Life May Soon Get Easier for (Some) Biotech Stocks. Here's Why.

Raising capital is a key concern for most businesses, but it's a particularly acute issue for biotechs approaching the commercialization of their first few products, and especially for those expecting to have substantial manufacturing expenses. Remember these two categories, as they're the groups that could soon pick up a new tailwind. As we all know, debt can have consequences, even if the tax shield is handy. If a biotech has no taxable income, there's nothing to offset the cost of interest payments. So u ...